{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-003735","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2024-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.430985+00:00","generated_at":"2026-06-04T09:09:07.034957+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"HOOKIPA Pharma Q4/FY2023 net loss $24.8M/$81.6M; cash $117.5M; HB-200 ORR 42%","bullets":["Net loss $24.8M (Q4) and $81.6M (FY2023), vs $12.3M and $64.9M in prior year.","Revenue $7.4M (Q4) and $20.1M (FY2023); R&D expenses $21.2M and $86.4M.","Cash and equivalents $117.5M at Dec 31, 2023, including $71M from capital raises and $15M in milestones.","HB-200 + pembrolizumab showed 42% objective response rate in 1L HPV16+ HNSCC; pivotal trial to start 2024.","Roche terminated HB-700 collaboration; HOOKIPA to regain rights; IND filing by April 2024 triggers final milestone."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-003735","json":"https://secwatch.observer/filing/0001558370-24-003735.json","markdown":"https://secwatch.observer/filing/0001558370-24-003735.md","text":"https://secwatch.observer/filing/0001558370-24-003735.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000155837024003735/0001558370-24-003735-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000155837024003735/hook-20240322x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:09:07.034957+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f969b40b7cc27734aed1273d71836847c6aab299","claim":"HOOKIPA Pharma Inc. reported financial results for the fourth quarter and full year 2023.","evidence_excerpt":"On March 22, 2024, HOOKIPA Pharma Inc. (the “Company”) announced Financial Results for the Fourth Quarter and Full Year 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1760542/000155837024003735/0001558370-24-003735-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}